Skip to main content

Table 6 Severity of gastric pathology by Hp status, 308 CANHelp project participants with histopathology data, 2008–2013

From: Burden of disease from Helicobacter pylori infection in western Canadian Arctic communities

Pathology Hp positive (n = 224) Hp negative (n = 84)  
n %a 95% CI n %a 95% CI χ2-p-valuee:
Normal histopathologyb
 No 223 99.6 99, 100 19 23 14, 32 0.000
 Yes 1 0.4 0, 2 65 77 68, 86
Active gastritisc
 None 7 3 1, 6 82 98 94, 100 0.000
 Mild 102 46 39, 52 2 2 0, 8
 Moderate 81 36 30, 42 0 0 0, 4
 Severe 32 14 10, 19 0 0 0, 4
Chronic gastritis
 None 2 1 0, 2 73 87 80, 94 0.000
 Mild 17 8 4, 11 10 12 5, 19
 Moderate 99 44 38, 51 1 1 0, 6
 Severe 106 47 41, 54 0 0 0, 4
Atrophy
 None 128 57 51, 64 84 100 96, 100 0.000
 Mild 68 30 24, 36 0 0 0, 4
 Moderate 23 10 6, 14 0 0 0, 4
 Severe 5 2 1, 5 0 0 0, 4
Intestinal metaplasia
 None 185 83 78, 88 80 95 91, 100 0.002
 Mild 23 10 6, 14 4 5 1, 12
 Moderate 13 6 3, 9 0 0 0, 4
 Severe 3 1 0, 4 0 0 0, 4
MALT hyperplasiad (n = 114; 96 HP+)
 None 3 3 1, 9 13 72 52, 93 0.000
 Mild 34 35 26, 45 5 28 10, 53
 Moderate 45 47 37, 57 0 0 0, 19
 Severe 14 15 8, 22 0 0 0, 19
Lymphoid aggregatesd (n = 194; 128 HP+)
 Present 74 58 49, 66 5 8 3, 17 0.000
Lymphoepithelial lesions
 Present 7 3 1, 6 0 0 0, 4 0.101
Dysplasia or Carcinoma
 Present 0 0 0, 2 0 0 0, 4 n/a
  1. Hp H. pylori, CI binomial Wald confidence interval (binomial exact CI for numerators < 10; one-sided binomial exact 97.5% CI for numerators of 0)
  2. aDistributions do not all sum 100% due to rounding
  3. bExcludes MALT hyperplasia or lymphoid aggregates; includes reactive gastropathy
  4. c2 H. pylori-positive participants lack classification for active gastritis
  5. dIn 2008, presence/absence of lymphoid aggregates was noted without grading MALT hyperplasia; after 2008, MALT hyperplasia was graded instead of noting presence/absence of lymphoid aggregates
  6. eFrom score test for trend of odds